• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.

作者信息

Abid Muhammad Bilal, Mughal Mustafa, Abid Muhammad Abbas

机构信息

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee.

Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee.

出版信息

JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.

DOI:10.1001/jamaoncol.2020.2367
PMID:32433719
Abstract
摘要

相似文献

1
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
2
Palliative Care for Patients With Cancer in the COVID-19 Era.新冠疫情时代癌症患者的姑息治疗
JAMA Oncol. 2020 Oct 1;6(10):1527-1528. doi: 10.1001/jamaoncol.2020.1938.
3
Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors.曾接触过免疫检查点抑制剂的癌症患者感染2019冠状病毒病（COVID-19）的临床结局
Cancer Commun (Lond). 2020 Aug;40(8):374-379. doi: 10.1002/cac2.12077. Epub 2020 Jul 15.
4
Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.COVID-19大流行期间的肿瘤护理服务：研究创新与结果的契机。
JCO Oncol Pract. 2020 Aug;16(8):431-434. doi: 10.1200/OP.20.00326. Epub 2020 May 28.
5
Management of Febrile Neutropenia Associated With SARS-CoV-2 Infection in a Patient With Cancer.癌症患者合并SARS-CoV-2感染的发热性中性粒细胞减少症的管理
JCO Oncol Pract. 2020 Jun;16(6):348-349. doi: 10.1200/OP.20.00197. Epub 2020 May 5.
6
Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.面对新冠疫情时胃肠道肿瘤学的实践调整：肿瘤学专家关于将患者风险降至最低的建议
JCO Oncol Pract. 2020 Jul;16(7):383-388. doi: 10.1200/OP.20.00239. Epub 2020 Apr 30.
7
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.免疫检查点抑制剂对病毒感染和新冠肺炎的潜在保护及治疗作用。
Immunotherapy. 2020 Oct;12(15):1111-1114. doi: 10.2217/imt-2020-0109. Epub 2020 Jun 29.
8
[COVID-19- what have we learned and where are we heading?].[新冠疫情——我们学到了什么，又将走向何方？]
Laeknabladid. 2020 Oct;106(10):449. doi: 10.17992/lbl.2020.10.598.
9
COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.新型冠状病毒肺炎：冠状病毒复制、发病机制及治疗策略
Cleve Clin J Med. 2020 Jun;87(6):321-327. doi: 10.3949/ccjm.87a.20047. Epub 2020 May 4.
10
Disparities in Cancer Outcomes Due to COVID-19-A Tale of 2 Cities.COVID-19导致的癌症治疗结果差异——两个城市的故事
JAMA Oncol. 2020 Oct 1;6(10):1531-1532. doi: 10.1001/jamaoncol.2020.3327.

引用本文的文献

1
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.一项关于BTK抑制剂泽布替尼在新冠病毒肺炎呼吸窘迫住院患者中的随机、安慰剂对照试验：免疫生物标志物及临床发现
Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024.
2
Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen.接受靶向B细胞成熟抗原的双特异性T细胞衔接器治疗的多发性骨髓瘤患者的持续性病毒感染
Haematologica. 2023 Nov 1;108(11):3186-3190. doi: 10.3324/haematol.2023.283003.
3
Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas.
实体癌或白血病/淋巴瘤靶向治疗的感染性并发症
Cancers (Basel). 2023 Mar 27;15(7):1989. doi: 10.3390/cancers15071989.
4
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry.异基因造血干细胞移植受者 COVID-19 结局：EPICOVIDEHA 登记研究结果。
Front Immunol. 2023 Feb 24;14:1125030. doi: 10.3389/fimmu.2023.1125030. eCollection 2023.
5
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞治疗后感染并发症、免疫重建和感染预防。
Bone Marrow Transplant. 2022 Oct;57(10):1477-1488. doi: 10.1038/s41409-022-01756-w. Epub 2022 Jul 15.
6
COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes.COVID-19 与合并症：风险、协同作用和临床结局。
Front Immunol. 2022 May 27;13:890517. doi: 10.3389/fimmu.2022.890517. eCollection 2022.
7
Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era.COVID-19 时代早期免疫调节剂与 CAR T 细胞免疫疗法
Lancet Oncol. 2022 Jan;23(1):16-18. doi: 10.1016/S1470-2045(21)00695-1.
8
Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential.肠道微生物组在 COVID-19 中的作用：对发病机制和治疗潜力的深入了解。
Front Immunol. 2021 Oct 14;12:765965. doi: 10.3389/fimmu.2021.765965. eCollection 2021.
9
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.嵌合抗原受体 T 细胞疗法的感染风险和 SARS-CoV-2 疫苗反应的决定因素：CAR-T 疗法的现状
Transplant Cell Ther. 2021 Dec;27(12):973-987. doi: 10.1016/j.jtct.2021.09.016. Epub 2021 Sep 27.
10
Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.抗 PD-1 封锁对 SARS-CoV-2 感染的潜在保护作用。
Biomed Pharmacother. 2021 Oct;142:111957. doi: 10.1016/j.biopha.2021.111957. Epub 2021 Jul 28.